Research Papers:

Identification of a three-miRNA signature as a blood-borne diagnostic marker for early diagnosis of lung adenocarcinoma

Yang Wang, Hua Zhao, Xujie Gao, Feng Wei, Xinwei Zhang, Yanjun Su, Changli Wang, Hui Li and Xiubao Ren _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:26070-26086. https://doi.org/10.18632/oncotarget.8429

Metrics: PDF 2635 views  |   HTML 3184 views  |   ?  


Yang Wang1,3,4,*, Hua Zhao1,3,4,*, Xujie Gao1,3,4, Feng Wei1,3,4, Xinwei Zhang2,3,4, Yanjun Su3,5, Changli Wang3,5, Hui Li1,3,4, Xiubao Ren2,3,4

1Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, 300060 Tianjin, China

2Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, 300060 Tianjin, China

3National Clinical Research Center of Cancer, 300060 Tianjin, China

4Key Laboratory of Cancer Immunology and Biotherapy, 300060 Tianjin, China

5Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, 300060 Tianjin, China

*These authors contributed equally to this work

Correspondence to:

Xiubao Ren, e-mail: [email protected]

Hui Li, e-mail: [email protected]

Keywords: lung adenocarcinoma, miRNA, plasma, diagnosis, biomarker

Received: January 12, 2016     Accepted: March 14, 2016     Published: March 27, 2016


Background: The subtypes of NSCLC have unique characteristics of pathogenic mechanism and responses to targeted therapies. Thus, non-invasive markers for diagnosis of different subtypes of NSCLC at early stage are needed.

Results: Based on the results from the screening and validation process, 3 miRNAs (miR-532, miR-628-3p and miR-425-3p) were found to display significantly different expression levels in early-stage lung adenocarcinoma, as compared to those in healthy controls. ROC analysis showed that the miRNA–based biomarker could distinguish lung adenocarcinoma from healthy controls with high AUC (0.974), sensitivity (91.5%), and specificity (97.8%). Importantly, these three miRNAs could also distinguish lung adenocarcinoma from lung benigh diseases and other subtypes of lung cancer.

Methods: Two hundreds and one early-stage lung adenocarcinoma cases and one hundreds seventy eight age- and sex-matched healthy controls were recruited to this study. We screened the differentially expressed plasma miRNAs using TaqMan Low Density Arrays (TLDA) followed by three-phase qRT-PCR validation. A risk score model was established to evaluate the diagnostic value of the plasma miRNA profiling system.

Conclusions: Taken together, these findings suggest that the 3 miRNA–based biomarker might serve as a novel non-invasive approach for diagnosis of early-stage lung adenocarcinoma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8429